You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
宜明昂科-B(01541.HK)與SynBioTx Inc.訂立授權及合作協議

格隆匯8月1日丨宜明昂科-B(01541.HK)發佈公吿,公司於2024年8月1日與SynBioTx Inc.(SynBioTx,Instil Bio, Inc. (NASDAQ:TIL)的全資附屬公司)訂立授權及合作協議,據此,公司同意授予SynBioTx在大中華地區(包括中國內地、中國香港特別行政區、中國澳門特別行政區及台灣)以外研究、開發及商業化若干靶向程序性細胞死亡配體1(PD-L1)及血管內皮生長因子(VEGF)的雙特異性抗體(包括候選產品IMM2510),以及若干靶向細胞毒性T淋巴細胞相關蛋白4(CTLA-4)的單克隆抗體(包括候選產品IMM27M)的獨家授權。

根據授權及合作協議,SynBioTx將獲得在大中華地區以外研究、開發及商業化若干靶向PD-L1及VEGF的雙特異性抗體(包括候選產品IMM2510),以及若干靶向CTLA-4的單克隆抗體(包括候選產品IMM27M)的獨家授權。公司將保留在大中華地區的開發及商業化權利。

根據授權及合作協議,公司將收取不超過50百萬美元的首付款及潛在近期付款(包括10百萬美元的首付款),以及不超過21億美元的商業、開發及監管里程碑付款(包括不超過270百萬美元的長期開發及監管里程碑付款以及不超過18億美元的商業里程碑付款),另收取按大中華地區以外全球銷售淨額的個位數至低兩位數比例計算的特許權使用費。所有擬收取的特許權使用費的期限應以各產品及各國家為基礎終止,直至該產品在該國首次商業銷售十週年、專利屆滿及監管獨佔期屆滿(以較晚者為準)為止。

集團將藉此機會,通過創新合作模式進一步加強全球合作網絡,最大限度發揮集團技術平台的科學及商業價值。綜上所述,董事會認為,訂立授權及合作協議符合公司及股東的整體最佳利益。

據悉,IMM2510由集團自主研發,是一款靶向VEGF及PD-L1的雙特異性分子,採用單克隆抗體 — 受體重組蛋白(mAb-Trap)結構。IMM2510能夠抑制血管生成,使腫瘤縮小,並使腫瘤細胞對免疫反應更敏感,同時通過阻斷PD-L1 ╱程序性細胞死亡蛋白1 (PD-1)相互作用及誘導Fc介導的抗體依賴的細胞毒性作用(ADCC) ╱抗體依賴的細胞吞噬作用(ADCP)活性激活T細胞、自然殺傷細胞及巨噬細胞。

SynBioTx Inc.是一家於2024年7月30日在美國特拉華州註冊成立的公司,是InstilBio, Inc.的全資附屬公司,主要從事臨牀研究及開發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account